Shin Nippon Biomedical Laboratories Management
Management criteria checks 2/4
Shin Nippon Biomedical Laboratories' CEO is Ryoichi Nagata, appointed in Jan 1991, has a tenure of 33.92 years. directly owns 2.46% of the company’s shares, worth ¥1.74B. The average tenure of the management team and the board of directors is 2.5 years and 9.5 years respectively.
Key information
Ryoichi Nagata
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 33.9yrs |
| CEO ownership | 2.5% |
| Management average tenure | 2.5yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00
Dec 19
Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00
Dec 02What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You
Nov 25Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27CEO
Ryoichi Nagata (66 yo)
33.9yrs
Tenure
JP¥144,061,000
Compensation
Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 33.9yrs | JP¥144.06m | 2.46% ¥ 1.7b | |
| Senior Executive Officer | 2.9yrs | no data | no data | |
| Managing Executive Officer | no data | no data | no data | |
| Senior MD of Corporate Development & Corporate Tax Administration and Director | 2.5yrs | no data | no data | |
| Senior Managing Executive Officer | no data | no data | no data | |
| Executive VP of Group Corporate Management & Global Business & Director | 20.5yrs | no data | 0.090% ¥ 63.4m | |
| Managing Executive Officer & GM of Fisheries Division | less than a year | no data | no data | |
| Senior MD | 1.9yrs | no data | no data | |
| Managing Executive Officer & President and Representative Director of SNBL Ina Research Center | no data | no data | no data | |
| Managing Executive Officer | less than a year | no data | no data | |
| Senior MD & Director | no data | no data | 0.043% ¥ 30.7m | |
| Executive VP | no data | no data | 40.32% ¥ 28.5b |
2.5yrs
Average Tenure
57yo
Average Age
Experienced Management: 2395's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 41.7yrs | JP¥144.06m | 2.46% ¥ 1.7b | |
| Senior MD of Corporate Development & Corporate Tax Administration and Director | 14.5yrs | no data | no data | |
| Senior Managing Executive Officer | no data | no data | no data | |
| Executive VP of Group Corporate Management & Global Business & Director | 22yrs | no data | 0.090% ¥ 63.4m | |
| Senior MD | 10.5yrs | no data | no data | |
| Senior MD & Director | 10.5yrs | no data | 0.043% ¥ 30.7m | |
| Executive VP | 4.5yrs | no data | 40.32% ¥ 28.5b | |
| Independent Outside Director | 9.5yrs | no data | 0.00096% ¥ 677.8k | |
| Independent Outside Director | 9.5yrs | no data | 0.00096% ¥ 677.8k | |
| Independent Outside Director | 4.5yrs | no data | 0.0098% ¥ 7.0m | |
| Independent Outside Director | 3.5yrs | no data | 0.0019% ¥ 1.4m | |
| Independent Outside Director | less than a year | no data | no data |
9.5yrs
Average Tenure
60yo
Average Age
Experienced Board: 2395's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 20:49 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuki Tsukamoto | BofA Global Research |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |